A sector market update described a rebound in biotech equity performance, with the iShares Biotechnology ETF up 34% over the prior 12 months and the SPDR S&P Biotech ETF up 39%, alongside a surge in IPO activity. It also reported that global licensing deals fell to about $48 billion in 41 transactions and that deal focus shifted toward clinical-stage assets. The snapshot suggests capital markets are reopening, but transaction terms and valuation discipline remain constrained—pressuring preclinical and discovery-heavy stories while rewarding clinical differentiation.